About vigabatrin tablets and oral solution
Vigabatrin, available as Sabril® tablets and powder for oral solution or Kigabeq® powder for oral solution, is a specialized antiepileptic medication primarily used for managing specific epilepsy syndromes. It serves as an irreversible inhibitor of GABA transaminase (GABA-T), which boosts gamma-aminobutyric acid (GABA) levels in the brain—the main inhibitory neurotransmitter—to help control excessive neuronal firing responsible for seizures. This mechanism reduces the propagation of abnormal hypersynchronous discharges, thereby decreasing seizure frequency and severity.
The medication is indicated for two main conditions: infantile spasms (West syndrome) in infants aged 1 month to 2 years as monotherapy, and refractory complex partial seizures (also known as focal impaired awareness seizures) in patients 2 years and older as adjunctive therapy when other treatments have failed. Due to serious risks, particularly permanent vision loss, vigabatrin carries FDA black box warnings and is only available through restricted programs like the Sabril REMS (Risk Evaluation and Mitigation Strategy).
In the UK and elsewhere, vigabatrin is prescribed under specialist supervision, often in hospital settings initially, with strict visual field monitoring protocols. It is not a first-line treatment owing to its risk-benefit profile but offers valuable efficacy in drug-resistant cases.
Types of medicine: tablet, powder for oral solution
- Sabril® 500 mg tablets: White, oval, film-coated tablets marked with ‘SABRIL 500’. Supplied in bottles of 100 tablets.
- Sabril® 500 mg powder for oral solution: White to off-white powder in 50 mg/mL strength when reconstituted, supplied in 25 g and 50 g sachets.
- Kigabeq® 100 mg/g oral powder: Similar powder formulation for precise pediatric dosing, available in multi-dose sachets.
Tablets are for adults and older children capable of swallowing, while powders are preferred for infants and young children, mixed with water, milk, or formula for administration via syringe or spoon.
Key facts
- Vigabatrin is used to treat infantile spasms (1 month–2 years) and refractory focal seizures (≥2 years).
- Treatment duration for infantile spasms is typically 6 months if effective; reassess periodically for focal seizures.
- Works by increasing GABA levels, slowing brain cell over-firing.
- Major risk: Permanent visual field defects (e.g., tunnel vision) in up to 30–50% of long-term users; requires lifelong monitoring.
- Available only via certified prescribers under REMS programs.
- Common side effects include drowsiness, irritability, weight gain; serious risks include suicidal thoughts and retinal damage.
About epilepsy and seizures
Epilepsy affects around 1 in 100 people, characterized by recurrent unprovoked seizures due to sudden electrical disturbances in the brain. Seizures vary: focal (partial) involve one brain area, potentially spreading; generalized affect both sides. Infantile spasms are a severe epileptic encephalopathy in babies, presenting as sudden stiffening or jackknife movements, often linked to poor neurodevelopmental outcomes if untreated. Refractory complex partial seizures resist multiple antiepileptics, severely impacting quality of life. Vigabatrin targets GABAergic inhibition to restore balance.
How vigabatrin works
Vigabatrin irreversibly binds GABA-T, the enzyme metabolizing GABA to succinic semialdehyde, causing a rapid, sustained increase in brain GABA concentrations. This enhances inhibitory neurotransmission, countering the hyperexcitability in epilepsy. Unlike reversible inhibitors, its effect persists until new enzyme is synthesized, providing prolonged seizure control. Studies confirm vigabatrin raises free and total GABA levels, reducing seizure propagation without directly affecting excitatory pathways. Efficacy is highest in infantile spasms (50–70% response rate) and tuberous sclerosis-related cases.
Dosage
Dosage is weight-based, titrated slowly to minimize side effects, with maximum daily limits. Always follow specialist guidance; do not adjust without consultation.
For infantile spasms (1 month–2 years)
| Age/Weight | Initial Dose | Titration | Maintenance |
|---|---|---|---|
| Under 3 kg | 25 mg/kg/day | Increase weekly | Up to 100 mg/kg/day |
| 3–18 kg | 50 mg/kg/day (single or divided) | To 100–150 mg/kg/day | 150 mg/kg/day max |
Administer as powder mixed in feeds; assess response in 2–4 weeks. Discontinue if no benefit.
For refractory focal seizures (≥2 years)
| Age Group | Initial Dose | Titration | Maintenance |
|---|---|---|---|
| Children 2–10 years (<10 kg) | 40 mg/kg/day | Increase weekly | Up to 100–150 mg/kg/day |
| 10+ years/Adult | 500 mg/day (divided BID) | Increase 500 mg weekly | 3 g/day max |
Combine with other AEDs; powder for precise dosing in children.
Missed dose
Take as soon as remembered unless near next dose; never double. Log misses for doctor review to prevent breakthrough seizures.
How and when to take vigabatrin
Tablets: Swallow whole with water, with/without food. Powder: Dissolve sachet in 10 mL water (do not heat); administer immediately, rinse residue. Give twice daily, spaced evenly. Use oral syringes for infants. Shake suspension well.
Side effects of vigabatrin
Vigabatrin has a notable side effect profile; report new symptoms promptly.
Common side effects
- Drowsiness, fatigue (20–40%)
- Irritability, agitation, hyperactivity
- Weight gain, increased appetite
- Headache, dizziness, tremor
- Vision changes (blurred, color vision issues)
Serious side effects
- Permanent visual field loss: Bilateral concentric constriction (tunnel vision), irreversible; occurs in 1/3 of adults, less detectable in infants.
- Retinal toxicity: Macular atrophy, reduced acuity.
- Psychiatric: Depression, aggression, suicidal ideation (black box).
- Allergic reactions: Rash, swelling.
- Bone marrow suppression, anemia (rare).
Monitor weight, behavior, and vision rigorously.
Visual (eye) monitoring
Mandatory due to vision loss risk. Baseline exam before start, then:
- Infants: Formal perimetry not feasible; use confrontational testing, fundoscopy every 3–6 months.
- Children/Adults: Visual field testing (e.g., perimetry) at baseline, 4 weeks, 3 months, then 6-monthly. Continue 3–6 months post-discontinuation.
Stop if defects detected or no seizure benefit in 3 months. Report to REMS: 1-888-457-4273.
Pregnancy and breastfeeding
Vigabatrin is Category C; potential fetal risks (teratogenicity in animals). Use only if benefits outweigh risks; discuss with specialist. Levels low in breast milk but monitor infant for sedation/seizures. Registry data limited.
Cautions of vigabatrin tablets and oral solution
- History of psychosis, renal impairment (adjust dose).
- Avoid abrupt stop (seizure risk); taper over weeks.
- Drug interactions: Minimal, but enhances CNS depressants; monitor with valproate, clobazam.
- Overdose: Somnolence, respiratory depression; seek emergency care.
Other medicines, food, drink and driving
May potentiate sedatives, alcohol, opioids. No major food interactions. Do not drive/operate machinery until effects known; vision loss impairs safety. UK DVLA notification required for epilepsy.
Frequently Asked Questions (FAQs)
How quickly does vigabatrin work for infantile spasms?
Response often within 2–4 weeks; discontinue if no improvement.
Can vigabatrin cure epilepsy?
No, it controls symptoms but does not cure; reassess need periodically.
What if vision monitoring shows problems?
Discontinue immediately; loss may progress despite stopping.
Is vigabatrin safe long-term?
Use shortest duration; risk of irreversible vision damage increases with time.
How to store vigabatrin powder?
Room temperature, dry place; reconstituted suspension stable 7 days refrigerated.
References
- Vigabatrin – StatPearls — NCBI Bookshelf. 2023-07-17. https://www.ncbi.nlm.nih.gov/books/NBK557579/
- Vigabatrin: Uses, Interactions, Mechanism of Action — DrugBank. 2024-01-01. https://go.drugbank.com/drugs/DB01080
- Sabril (vigabatrin) – FDA Postmarket Drug Safety Information — U.S. Food and Drug Administration. 2009-08-21 (updated). https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/sabril-vigabatrin
- Vigabatrin — Epilepsy Foundation. 2024-01-01. https://www.epilepsy.com/tools-resources/seizure-medication-list/vigabatrin
- Sabril (vigabatrin) Molina Clinical Policy — Molina Healthcare. 2023-01-01. https://www.molinahealthcare.com/providers/wa/medicaid/resource/PDF/sabril-vigabatrin-mcp260.pdf
- Vigabatrin – Uses and Side Effects — CURE Epilepsy. 2024-01-01. https://www.cureepilepsy.org/understanding-epilepsy/treatments/epilepsy-medications/vigabatrin/
- Sabril (vigabatrin) Official Site — Lundbeck. 2024-01-01. https://www.sabril.net
